Traders shift to short-term tactics in response to tariffs — Web3 CEO
In an interview with Cointelegraph, the CEO said the tariffs have created headline-driven volatility across financial markets that can shift sentiment, often oscillating between extremes in a single day. This has made markets far more difficult to trade. Yasavolian added:
'Trading behavior has essentially changed to be more intraday — when you have your profit, you just take it when you can get it. So, behavior is essentially cutting confidence on further upside or downside if you are taking a position on longing or shorting.'
'That is the kind of behavior we have witnessed and we have shifted to this strategy internally as well,' the CEO told Cointelegraph.
Although the initial volatility has subsided and markets have somewhat recovered from the initial Trump tariff shock, a cloud of uncertainty still hangs over all risk-on markets as traders and investors grapple with the shifting macroeconomic landscape.
Trade tariffs shake investor confidence and maximize economic uncertainty
Crypto investors are watching negotiations between the US and China for any sign of a lasting trade deal, which analysts predict will cause a sustained price rally in altcoins and Bitcoin.
On May 25, President Trump announced a delay in tariffs on European Union (EU) goods, extending the tariff deadline to July 9. Crypto markets reacted positively to the news, with the price of BTC climbing by over 3% in an intraday move.
'The EU and US share the world's most consequential and close trade relationship. Europe is ready to advance talks swiftly and decisively,' president of the EU Commission Ursula von der Leyen wrote in a May 25 X post.
Despite the political reassurances of productive trade talks and a potential resolution to the tensions, some analysts say that any progress in negotiations, tariff exemptions, or softening of the rhetoric is illusory, with much of it presented for political optics.
Source: https://cointelegraph.com/news/traders-shift-short-term-tactics-response-tariffs
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13-06-2025
- Yahoo
Judge Blocks Trump Admin From Deploying National Guard in Los Angeles
As California Governor Newsom and President Trump continue to square off over the administration's militarized response to anti-deportation protests in Los Angeles, a federal judge has blocked the activation of National Guard troops in the city. Judge Charles Breyer ordered the Trump administration to return control of the guard to Newsom, saying the president had acted illegally in federalizing 4,000 guard troops against the governor's wishes. More from Variety PBS, NPR Could Lose $1.1 Billion in Funding After Trump's Rescission Bill Narrowly Passes House The Chrisleys Claimed Political Persecution to Get a Trump Pardon, but Records Tell a Different Story Bob Costas Slams Trump's 'Ongoing Assaults' on Free Press and Warns Against 'MAGA Media': 'Democracy As We Know It Is Under Attack' 'The Court concludes that Plaintiffs have demonstrated that the balance of equities tips in their favor and that an injunction restraining the President's use of military force in Los Angeles is in the public interest,' Breyer wrote. Protests have lasted nearly a week in Los Angeles following a series of raids conducted by Immigration and Customs Enforcement around Southern California. Trump declared on June 7 that the protesters were engaged in 'rebellion against the authority of the Government of the United States,' and called out the guard. The ruling cites several dictionary definitions of 'rebellion' and concludes that the protests — including sporadic acts of violence — does not qualify. 'The protests in Los Angeles fall far short of 'rebellion,'' Breyer wrote. The order does not goes into effect until 12 p.m. PT on Friday; the Trump administration is expected to seek an appeal beforehand. The ruling came hours after Sen. Alex Padilla was forcibly removed from a press conference in Los Angeles, taken to the ground, and put in handcuffs. The moment became an instant media firestorm, leading news sites, playing on cable news all day, and bringing condemnation from Democrats on the Senate floor. In an interview Thursday evening on MSNBC's 'The Beat with Ari Melber,' Padilla said he was listening to a press conference from Kristi Noem, the secretary of homeland security, when 'the political rhetoric got to be too much.' 'At one point, it was just too much to take,' Padilla said in his first interview about the encounter. 'Not the first, but the second attack on the political leadership of California and this notion that Donald Trump and Kristi Noem have to come in and rescue the people of Los Angeles from Gavin Newsom and Karen Bass? It was too much. And so I spoke up.' Noem appeared at the FBI building in Westwood to vow to continue to crack down on the protests. 'We are not going away,' Noem said. 'We are staying here to liberate this city from the socialists and the burdensome leadership that this governor and this mayor have placed on this country.' That was the point at which the senator reacted, moving toward the front of the room and raising his voice to ask a question. The agents apparently did not recognize Padilla — the lesser known of California's two senators — and grabbed him. He identified himself as he was pushed backwards and out of the room. 'To suggest that they have to come into Los Angeles to restore order — ' he told interviewer Jacob Soboroff. 'You know Los Angeles. It's a big, spread-out city. The images that we've seen over the course of the last week of some vandalism, some violence, et cetera, that's wrong. And I denounce it. But it's very small and very contained in a big metropolis of the Los Angeles area. So the National Guard was not necessary.' He said he did talk with Noem afterward, but never got a scheduled briefing on the federal response. 'If they're allowed to do this in Los Angeles, they can and they will do this in any corner of the country,' Padilla said. Best of Variety New Movies Out Now in Theaters: What to See This Week 'Harry Potter' TV Show Cast Guide: Who's Who in Hogwarts? 25 Hollywood Legends Who Deserve an Honorary Oscar
Yahoo
13-06-2025
- Yahoo
Trump's Military Parade: Cost, Equipment and What to Expect
In celebration of the Army's 250th Birthday, the largest U.S. military parade in decades is scheduled for Flag Day—also President Trump's 79th birthday. Sign in to access your portfolio
Globe and Mail
13-06-2025
- Globe and Mail
NSCLC Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 10+ Companies and 10+ Therapies
DelveInsight's, 'Non-Small-Cell Lung Cancer Pipeline Insight 2025' report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Non-Small-Cell Lung cancer (NSCLC) pipeline landscape. It covers the NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NSCLC pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the NSCLC Treatment Landscape. Click here to read more @ NSCLC Pipeline Outlook Key Takeaways from the NSCLC Pipeline Report In June 2025, Revolution Medicines Inc. announced a study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel. This is a global, randomized, open-label, Phase 3 study designed to evaluate whether treatment with daraxonrasib will improve progression free survival (PFS) or overall survival (OS) compared to docetaxel chemotherapy in patients with NSCLC who were previously treated. Patients will be randomized in a 1:1 ratio to receive daraxonrasib or docetaxel chemotherapy. In June 2025, Amgen conducted a study is to characterize safety and efficacy of 2 dose levels of AMG 193 by investigator, and to evaluate AMG 193 monotherapy efficacy by Blinded Independent Central Review (BICR). In June 2025, Allist Pharmaceuticals Inc. organized a Phase 3 clinical study to assess the efficacy and safety of adjuvant treatment with firmonertinib versus placebo in participants with Stage IB-IIIB NSCLC with uncommon EGFR mutations (exon 20 insertions, PACC and classical-like mutations) after complete surgical resection with or without adjuvant chemotherapy. In June 2025, AstraZeneca announced a Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type advanced or metastatic NSCLC. DelveInsight's NSCLC pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for NSCLC treatment. The leading NSCLC Companies such as GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, and Sanofi are actively involved in research and development. Additionally, innovative biotechs like IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc. and others. Promising NSCLC Pipeline Therapies such as Brigatinib, Tyrosine kinase inhibitor, sintilimab combined with anlotinib, Osimertinib, Gefitinib, SSGJ-707, Vandetanib, Atezolizumab, Tiragolumab and others. Stay informed about the cutting-edge advancements in NSCLC treatments. Download for updates and be a part of the revolution in cancer care @ NSCLC Clinical Trials Assessment NSCLC Emerging Drugs Profile AMG 510: Amgen AMG 510 is being developed by Amgen. Phase 1 clinical trials were completed in late 2020. Because the G12C KRAS mutation is relatively common in some cancer types, 14% of non-small-cell lung cancer adenocancer patients and 5% of colorectal cancer patients, and AMG 510 is the first drug candidate to target this mutation, there have been high expectations for the drug. The Food and Drug Administration has granted a fast track designation to AMG 510 for the treatment of metastatic non-small-cell lung cancer with the G12C KRAS mutation. The drug is in preregistration stage for the treatment of NSCLC. CMP 001: Cytos Biotechnology CMP 001 is a short piece of DNA, called an oligonucleotide that Checkmate designed to mimic the DNA of bacteria. It encapsulated the DNA in noninfectious virus-like particles, or VLPs. The company created CMP-001 to be administered directly to a tumor. When this occurs, the immune system sees VLPs as foreign. It generates immune cells called antigen presenting cells that release the DNA from the VLPs. CMP 001 is in phase 1 of clinical trials for the treatment of non-small cell lung cancer. The NSCLC Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of NSCLC with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for NSCLC Treatment. NSCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. NSCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different NSCLC mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the NSCLC market Learn more about NSCLC Drugs opportunities in our groundbreaking NSCLC research and development projects @ NSCLC Unmet Needs NSCLC Companies GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, and Sanofi are actively involved in research and development. Additionally, innovative biotechs like IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc. and others. Non-Small-Cell Lung cancer (NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Subcutaneous Intravenous Oral Parenteral Intramuscular Molecule Type NSCLC Products have been categorized under various Molecule types such as Small molecules Peptides Polymer Gene Therapy Monoclonal antibodies Product Type Discover the latest advancements in NSCLC treatment by visiting our website. Stay informed about how we're transforming the future of neurology @ NSCLC Market Drivers and Barriers, and Future Perspectives Scope of the NSCLC Pipeline Report Coverage- Global NSCLC Companies- GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, and Sanofi are actively involved in research and development. Additionally, innovative biotechs like IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc. and others. NSCLC Pipeline Therapies- Brigatinib, Tyrosine kinase inhibitor, sintilimab combined with anlotinib, Osimertinib, Gefitinib, SSGJ-707, Vandetanib, Atezolizumab, Tiragolumab and others. NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of NSCLC Pipeline on our website @ NSCLC Emerging Drugs and Companies Table of Contents Introduction Executive Summary Non-Small-Cell Lung cancer (NSCLC): Overview Pipeline Therapeutics Therapeutic Assessment Non-Small-Cell Lung cancer (NSCLC) – DelveInsight's Analytical Perspective In-depth Commercial Assessment Late Stage Products (Pre Registration) AMG 510: Amgen Drug profiles in the detailed report….. Mid Stage Products (Phase II) Drug Name: Company Name Drug profiles in the detailed report….. Early Stage Products (Phase I) CMP 001: Cytos Biotechnology Inactive Products Non-Small-Cell Lung cancer (NSCLC) Key Companies Non-Small-Cell Lung cancer (NSCLC) Key Products Non-Small-Cell Lung cancer (NSCLC)- Unmet Needs Non-Small-Cell Lung cancer (NSCLC)- Market Drivers and Barriers Non-Small-Cell Lung cancer (NSCLC)- Future Perspectives and Conclusion Non-Small-Cell Lung cancer (NSCLC) Analyst Views Non-Small-Cell Lung cancer (NSCLC) Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
